Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBIT Margin (2017 - 2025)

Aclaris Therapeutics has reported EBIT Margin over the past 9 years, most recently at 1755.52% for Q4 2025.

  • Quarterly results put EBIT Margin at 1755.52% for Q4 2025, down 67339.0% from a year ago — trailing twelve months through Dec 2025 was 975.91% (down 21778.0% YoY), and the annual figure for FY2025 was 975.91%, down 21773.0%.
  • EBIT Margin for Q4 2025 was 1755.52% at Aclaris Therapeutics, down from 519.82% in the prior quarter.
  • Over the last five years, EBIT Margin for ACRS hit a ceiling of 23.03% in Q4 2023 and a floor of 1755.52% in Q4 2025.
  • Median EBIT Margin over the past 5 years was 1059.02% (2024), compared with a mean of 944.07%.
  • Peak annual rise in EBIT Margin hit 123753bps in 2024, while the deepest fall reached -105910bps in 2024.
  • Aclaris Therapeutics' EBIT Margin stood at 1525.18% in 2021, then soared by 75bps to 375.07% in 2022, then soared by 94bps to 23.03% in 2023, then tumbled by -4598bps to 1082.13% in 2024, then crashed by -62bps to 1755.52% in 2025.
  • The last three reported values for EBIT Margin were 1755.52% (Q4 2025), 519.82% (Q3 2025), and 1035.9% (Q2 2025) per Business Quant data.